Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
20132.0k citationsPaul Rutgeerts, Stephen B. Hanauer et al.profile →
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
20031.6k citationsFilip Baert, Maja Noman et al.profile →
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
20041.3k citationsGeert D’Haens, Gert Van Assche et al.profile →
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
20121.2k citationsAndré D’Hoore, Gerassimos J. Mantzaris et al.Journal of Crohn s and Colitisprofile →
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
20101.1k citationsGert Van Assche, Jean‐Frédéric Colombel et al.Journal of Crohn s and Colitisprofile →
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis
20101.0k citationsGert Van Assche, Gerassimos J. Mantzaris et al.Journal of Crohn s and Colitisprofile →
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
2011946 citationsWilliam J. Sandborn, Gert Van Assche et al.Gastroenterologyprofile →
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
2005789 citationsGert Van Assche, Séverine Vermeire et al.profile →
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
2019787 citationsWilliam J. Sandborn, Remo Panaccione et al.profile →
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial
2016738 citationsGert Van Assche, Jean‐Frédéric Colombel et al.profile →
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
2009648 citationsFilip Baert, Gert Van Assche et al.Gastroenterologyprofile →
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis
2012638 citationsGerassimos J. Mantzaris, Séverine Vermeire et al.Journal of Crohn s and Colitisprofile →
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
2015636 citationsNiels Vande Casteele, Marc Ferrante et al.Gastroenterologyprofile →
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
2012628 citationsGeert D’Haens, Marc Ferrante et al.profile →
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease
2009533 citationsFabian Schnitzler, Marc Ferrante et al.profile →
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
2012460 citationsPaul Rutgeerts, Gert Van Assche et al.Gastroenterologyprofile →
Author Peers
Peers are selected by citation overlap in the author's most active subfields.
citations ·
hero ref
Countries citing papers authored by Gert Van Assche
Since
Specialization
Citations
This map shows the geographic impact of Gert Van Assche's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gert Van Assche with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gert Van Assche more than expected).
This network shows the impact of papers produced by Gert Van Assche. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gert Van Assche. The network helps show where Gert Van Assche may publish in the future.
Co-authorship network of co-authors of Gert Van Assche
This figure shows the co-authorship network connecting the top 25 collaborators of Gert Van Assche.
A scholar is included among the top collaborators of Gert Van Assche based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Gert Van Assche. Gert Van Assche is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Stappen, Thomas Van, L. Bollen, Niels Vande Casteele, et al.. (2016). Analytical and clinical validation of a rapid point-of-care assay for infliximab quantification in patients with ulcerative colitis. 10.1 indexed citations
6.
Machiels, Kathleen, Wiebe Vanhove, João Sabino, et al.. (2015). Intestinal microbial signature predicts postoperative Crohn's disease recurrence following ileocaecal resection with ileocolonic anastomosis. Ghent University Academic Bibliography (Ghent University).1 indexed citations
7.
Papamichael, Konstantinos, Thomas Billiet, Marc Ferrante, et al.. (2015). Long-term outcome of IBD patients with primary non-response to anti-TNF therapy. 9.3 indexed citations
8.
Billiet, Thomas, Isabelle Cleynen, Vera Ballet, et al.. (2015). Disease burden outweighs the impact of drug concentrations and antibodies to infliximab in primary non-response to infliximab in Crohn's disease patients. 9.2 indexed citations
9.
Wauters, Lucas, Steven Joniau, Patrick Verschueren, et al.. (2015). Anti-TNF treatment and renal cell carcinoma in patients with inflammatory bowel disease, rheumatoid arthritis and spondyloarthropathy: trigger or cure?. 9.1 indexed citations
Casteele, Niels Vande, Ann Gils, Vera Ballet, et al.. (2013). Randomised Controlled Trial of Drug Level Versus Clinically Based Dosing of Infliximab Maintenance Therapy in IBD: Final Results of the TAXIT Study. United European Gastroenterology Journal. 1.27 indexed citations
Cleynen, Isabelle, Wouter Van Moerkercke, Niels Vande Casteele, et al.. (2011). Anti-TNF induced skin manifestations in IBD patients: characterization and search for predisposing factors. Open Repository and Bibliography (University of Liège).5 indexed citations
14.
Drobne, David, Peter Bossuyt, Christine Breynaert, et al.. (2011). Long term evolution and impact of immunomodulator cotreatment and withdrawal on infliximab on trough levels in 223 patients with Crohn's disease. Open Repository and Bibliography (University of Liège).2 indexed citations
15.
Arijs, Ingrid, Roel Quintens, Leentje Van Lommel, et al.. (2008). Effect of infliximab treatment on colonic mucosal gene expression profiles in patients with inflammatory bowel disease. Open Repository and Bibliography (University of Liège).1 indexed citations
16.
Schnitzler, Fabian, Marc Ferrante, Maja Noman, et al.. (2007). Intentional treatment with infliximab during pregnancy in women with inflammatory bowel disease. Gastroenterology. 132(4).11 indexed citations
17.
Hommes, DW, Filip Baert, Gert Van Assche, et al.. (2006). The ideal management of Crohn's disease: Top down versus step up strategies, a randomized controlled trial. Ghent University Academic Bibliography (Ghent University).29 indexed citations
18.
Ferrante, Marc, Marieke Pierik, Liesbet Henckaerts, et al.. (2006). A panel of anti-glycan antibodies (gASCA, ALCA, ACCA and AMCA) in the diagnosis and differential diagnosis of IBD. Ghent University Academic Bibliography (Ghent University).1 indexed citations
19.
Hommes, DW, Filip Baert, Gert Van Assche, et al.. (2005). A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): Top-down versus step-up strategies. Ghent University Academic Bibliography (Ghent University).24 indexed citations
20.
Rutgeerts, Paul, Geert D’Haens, Filip Baert, et al.. (2004). Randomized placebo controlled trial of pro- and prebiotics (synbiotics cocktail) for maintenance of infliximab induced remission of luminal Crohn's disease (CD). UCL Discovery (University College London).11 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.